{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T23:20:37Z","timestamp":1770765637436,"version":"3.50.0"},"reference-count":25,"publisher":"Impact Journals, LLC","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,8,8]]},"DOI":"10.18632\/oncotarget.18120","type":"journal-article","created":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T05:43:02Z","timestamp":1495604582000},"page":"52072-52077","source":"Crossref","is-referenced-by-count":17,"title":["The \u201c4 plus 2\u201d rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study"],"prefix":"10.18632","volume":"8","author":[{"given":"Dario","family":"Roccatello","sequence":"first","affiliation":[{"name":"Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"},{"name":"Nephrology and Dialysis Unit, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"},{"name":"Nephrology and Dialysis Unit, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirella","family":"Alpa","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Naretto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Radin","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Fenoglio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Baldovino","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"},{"name":"Nephrology and Dialysis Unit, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Menegatti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Rees","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Scott","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Feighery","year":"2012","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1002\/art.34590","article-title":"How can we predict the risk of relapse in antineutrophil cytoplasmic antibody-associated vasculitis? Comment on the article by Walsh et al","volume":"64","author":"Fischereder","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"74","key":"5","first-page":"177","article-title":"Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials","volume":"2015","author":"Luqmani","journal-title":"Ann Rheum Dis"},{"key":"6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jayne","year":"2010","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Sejismundo","year":"2010","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Jayne","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"9","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Jayne","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","article-title":"Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients","volume":"53","author":"Guillevin","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2215\/CJN.07340713","article-title":"Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis","volume":"9","author":"Niles","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000329535","article-title":"Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis","volume":"34","author":"Baldovino","year":"2011","journal-title":"Am J Nephrol"},{"key":"13","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis","volume":"64","author":"Falk","year":"2012","journal-title":"Arthritis Rheum"},{"key":"14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Mirapeix","year":"2003","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Jayne","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/art.39450","article-title":"Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener\u2019s) or Microscopic Polyangiitis","volume":"68","author":"Imbert","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/art.20234","article-title":"Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis","volume":"51","author":"Stegeman","year":"2004","journal-title":"Arthritis Rheum"},{"key":"18","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener\u2019s): ten-year experience at a single center","volume":"64","author":"Specks","year":"2012","journal-title":"Arthritis Rheum"},{"key":"19","unstructured":"Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis (MAINRITSAN 2)ClinicalTrials.gov Identifier NCT01731561(Last Access on 24.04.2017)."},{"key":"20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12026-016-8827-5","article-title":"Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature","volume":"65","author":"Roccatello","year":"2017","journal-title":"Immunol Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.autrev.2015.07.017","article-title":"A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment","volume":"14","author":"Menegatti","year":"2015","journal-title":"Autoimmun Rev"},{"key":"22","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1093\/ndt\/gfr109","article-title":"Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy","volume":"26","author":"Modena","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000445841","article-title":"Improved (4 plus 2) Rituximab protocol for severe cases of mixed cryoglobulinemia: a 6-year observational study","volume":"43","author":"Menegatti","year":"2016","journal-title":"Am J Nephrol"},{"key":"24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Kallenberg","year":"2013","journal-title":"Arthritis Rheum"},{"key":"25","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Muir","year":"2009","journal-title":"Ann Rheum Dis"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T19:36:59Z","timestamp":1750275419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":25,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2017,8,8]]}},"alternative-id":["18120","28881714"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.18120","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,23]]}}}